PDCD1 and hepatocellular carcinoma: A real-world study of HAIC combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors (TKIs) for advanced HCC showed that HAIC + anti-PD-1 antibody + oral TKIs were effective and safe.